Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
about
Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome.Irritable bowel syndrome: a clinical reviewThe Effect of DA-6034 on Intestinal Permeability in an Indomethacin-Induced Small Intestinal Injury Model.Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children.More negative self-esteem and inferior coping strategies among patients diagnosed with IBS compared with patients without IBS--a case-control study in primary care.Irritable bowel syndrome: the problem and the problem of treating it - is there a role for probiotics?Cytokine Response after Stimulation with Key Commensal Bacteria Differ in Post-Infectious Irritable Bowel Syndrome (PI-IBS) Patients Compared to Healthy Controls.The gut microbiota keeps enteric glial cells on the move; prospective roles of the gut epithelium and immune systemStress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome.Molecular and cellular mechanisms of tight junction dysfunction in the irritable bowel syndromeThe Impact of Lactobacillus casei on the Composition of the Cecal Microbiota and Innate Immune System Is Strain SpecificBifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed MiceIn vitro prevention of salmonella lipopolysaccharide-induced damages in epithelial barrier function by various lactobacillus strains.Indication of immune activation in patients with perceived food hypersensitivity.Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia.Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome.Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome.Nutritional Impact of Dietary Plasma Proteins in Animals Undergoing Experimental Challenge and Implications for Patients with Inflammatory Bowel Disorders: A Meta-analysis.Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions.Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome.Phenotypic variation in Blastocystis sp. ST3Maturation Phenotype of Peripheral Blood Monocyte/Macrophage After Stimulation with Lipopolysaccharides in Irritable Bowel Syndrome.Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota.New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.Systematic review and meta-analysis of traditional Chinese medicine in the treatment of constipation-predominant irritable bowel syndrome.Psychological stress-induced colonic barrier dysfunction: Role of immune-mediated mechanisms.Differential expression of microRNA related to irritable bowel syndrome in a rabbit model.Repeated water avoidance stress induces visceral hypersensitivity: Role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor.Oral probiotic treatment of Lactobacillus rhamnosus Lcr35® prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress.Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats.Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats.
P2860
Q33461640-166AE389-F4DB-40CD-90A2-EF0D038ACE9AQ34168517-D6553647-CAA9-47DD-B746-AC5C5BE1406AQ34523555-DCF0576A-D5C5-4305-9957-DDAC377C1BDAQ34852895-A13BB7B1-040F-436A-8804-687DCDA96935Q35048084-B9C50C24-9C43-43EE-8043-F6B621E4DBB0Q35231621-E6DCC6B1-8A89-4C91-A8A0-46805F5DE77EQ35772245-FBB595C3-CB66-4B08-9B6A-DD1172F3129DQ35838330-60E344F9-0BD6-4A78-95D4-F529F3E97C60Q35867820-30C6EAC2-5ACC-4201-AEBE-4B5CAE5917AEQ35919870-2920A9F1-F63C-4AD1-8226-25ACFDF1665EQ36034914-E7EB6F86-38B7-4018-A631-C19162BC3E9EQ36875133-6DCEE310-F45E-4535-81B4-1D29BF3F6A4BQ36948517-D8610C4C-C0E4-483E-B3C2-E43B7EE81BCCQ38159446-ED581BA8-EA77-4FD3-98E2-EBCFBF350B30Q38192977-361C7D7A-E79A-4BF1-9D50-DA45778A4257Q38193901-376C570A-3983-40D1-9734-8727933ADE97Q38473099-7B2EF004-DE55-4B1A-9F4D-B3614BA0760DQ38587570-4ED06933-E8BE-49F0-89AD-91267E157810Q38800981-249BC9E8-33EB-4DCD-B63A-9E9E9628B695Q38810529-8D744DAF-D952-4CBD-9D72-2362CA743F3CQ41760266-E9C082DB-E78C-4060-BC85-47D31E0956F9Q42292634-C6E3F190-D6DD-464A-B65A-03F19310861FQ42356646-9B6B1A0E-22F0-46B5-90AC-98506B69386FQ42695148-280812B9-75C0-47EF-BB1A-D99406EE9C74Q47119969-28246229-9282-4072-804A-D82AE94E7DB5Q48117039-678A2F45-C00A-4F38-A144-25B12AAC0B36Q48137909-0AF66B6D-1F19-4720-8D6C-61D85B679F49Q48261094-A46EAEF7-C8DF-48F1-AF1C-EEB114ABB415Q48313903-CDD1B6A2-52C6-45A1-8E25-F69BF0858717Q50178398-F5EF505F-F8CF-497E-90A2-D843B2E08771Q51372487-A01B68E3-53C2-4FA7-BCD1-1A65FAF6CEDD
P2860
Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Mucosal permeability and immun ...... s in irritable bowel syndrome.
@ast
Mucosal permeability and immun ...... s in irritable bowel syndrome.
@en
Mucosal permeability and immun ...... s in irritable bowel syndrome.
@nl
type
label
Mucosal permeability and immun ...... s in irritable bowel syndrome.
@ast
Mucosal permeability and immun ...... s in irritable bowel syndrome.
@en
Mucosal permeability and immun ...... s in irritable bowel syndrome.
@nl
prefLabel
Mucosal permeability and immun ...... s in irritable bowel syndrome.
@ast
Mucosal permeability and immun ...... s in irritable bowel syndrome.
@en
Mucosal permeability and immun ...... s in irritable bowel syndrome.
@nl
P2093
P1476
Mucosal permeability and immun ...... cs in irritable bowel syndrome
@en
P2093
Cesare Cremon
Giovanni Barbara
Lara Bellacosa
Lisa Zecchi
Marco Marcellini
Roberto Corinaldesi
Vincenzo Stanghellini
P356
10.1097/MCG.0B013E318264E918
P478
P577
2012-10-01T00:00:00Z